Antimicrobial stewardship (AMS) is an approach aimed at promoting sensible use of antimicrobials, in an effort to preserve their future effectiveness.^1,2 In clinical practice, stewardship translates as coordinated action to improve the use of anti-infectives and measure its appropriateness.¹

The overarching goal of AMS is 3-fold:³

1. Prescribe the appropriate anti-infective to patients
    
2. Prevent antimicrobial overuse, misuse, and abuse
    
3. Minimise the development of resistance

The principles of AMS are based on Public Health England’s ‘Start Smart – Then Focus’ guide, first published in 2011 and last updated in 2015, with information on implementing a stewardship programme, prescribing guidelines, and quality assurance measures.⁴ However, the toolkit was developed for broad antimicrobial use, without guidance specific to antifungal stewardship.

The terms ‘antimicrobial’ and ‘antibacterial’ are often used interchangeably, particularly in the context of resistance and stewardship. However, it’s important to note that antimicrobial is an umbrella term that covers all anti-infective therapies, including antivirals, antifungals, antibiotics, and antiparasitics.^1,5

At Pfizer, we have a long-standing commitment to tackling antimicrobial resistance, collaborating with the NHS and other stakeholders. We support an extensive range of initiatives that go beyond the sale of our medicines, including public awareness and educational programmes, education of healthcare professionals, responsible commercial and manufacturing activities, and investment in surveillance programmes.

ABS, antibacterial stewardship; AFS, antifungal stewardship; AMS, antimicrobial stewardship; PHE, Public Health England; TDM, therapeutic drug monitoring.

Prescribing Information:

Click here for CRESEMBA® (isavuconazole) prescribing information
Click here here for Zavicefta® (ceftazidime and avibactam) prescribing information
Click here for Zinforo® (ceftaroline fosamil) prescribing information

References: